We would like to propose that it may be possible to use a solitary dose of Elonva
(corifollitrophin alpha) as the sole gonadotrophin (FSH) stimulant for the vast majority of
women undergoing IVF, assuming that it is possible that "coasting" (withholding short acting
rFSH) from day 8 of the stimulation until trigger/ oocyte retrieval will still result in a
significant number of mature oocytes being produced and an acceptable pregnancy rate.